Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Targeted Therapy
100%
Tumor Necrosis Factor-α
100%
Psoriatic Arthritis
100%
Comparative Effectiveness
100%
Biologic Therapy
100%
Phosphodiesterase 4 (PDE4)
100%
Interleukin-12 (IL-12)
83%
Interleukin-17 (IL-17)
50%
Nave
33%
Adjusted Relative Risk
33%
Etanercept
16%
Potential Confounders
16%
Poisson Regression
16%
Treatment Choice
16%
Treatment Efficacy
16%
Inflammatory Arthritis
16%
Infliximab
16%
Retrospective Cohort
16%
Commercially Insured
16%
Robust Variance
16%
PDE4 Inhibitor
16%
Adalimumab
16%
Golimumab
16%
Data Warehouse
16%
Glucocorticoid Use
16%
Certolizumab Pegol
16%
Medicare Advantage
16%
Effectiveness Criteria
16%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
16%
Arthritis Treatment
16%
Secukinumab
16%
Apremilast
16%
Ustekinumab
16%
Tumor Necrosis Factor Inhibitor (TNFi)
16%
Claims-based Algorithm
16%
Ixekizumab
16%
Medicine and Dentistry
Targeted Therapy
100%
Tumor Necrosis Factor
100%
Psoriatic Arthritis
100%
Biologic Therapy
100%
Interleukin 12
83%
Biological Product
66%
Interleukin 17
50%
Glucocorticoid
16%
Medicare
16%
Arthritis
16%
Infliximab
16%
Rheumatoid Arthritis
16%
TNF Inhibitor
16%
Etanercept
16%
Phosphodiesterase IV Inhibitor
16%
Disease Modifying Antirheumatic Drug
16%
Ustekinumab
16%
Adalimumab
16%
Certolizumab Pegol
16%
Golimumab
16%
Apremilast
16%
Ixekizumab
16%
Secukinumab
16%
Inflammatory Arthritis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Biological Product
100%
Psoriatic Arthritis
100%
Interleukin 12
83%
Interleukin 17
50%
Rheumatoid Arthritis
16%
Etanercept
16%
Glucocorticoid
16%
Arthritis
16%
Infliximab
16%
Phosphodiesterase IV Inhibitor
16%
Disease Modifying Antirheumatic Drug
16%
Adalimumab
16%
Tumor Necrosis Factor Inhibitor
16%
Golimumab
16%
Certolizumab Pegol
16%
Ustekinumab
16%
Ixekizumab
16%
Secukinumab
16%
Apremilast
16%
Inflammatory Arthritis
16%
Immunology and Microbiology